Vivek Roy
About
Vivek Roy is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Vivek Roy has authored 203 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Hematology, 76 papers in Oncology and 66 papers in Molecular Biology. Recurrent topics in Vivek Roy's work include Multiple Myeloma Research and Treatments (93 papers), Protein Degradation and Inhibitors (38 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Vivek Roy is often cited by papers focused on Multiple Myeloma Research and Treatments (93 papers), Protein Degradation and Inhibitors (38 papers) and Chronic Lymphocytic Leukemia Research (31 papers). Vivek Roy collaborates with scholars based in United States, United Kingdom and Egypt. Vivek Roy's co-authors include Robert C. Flanigan, Nikhil C. Munshi, Patrick C. McGrath, J. R. Caton, Sydney E. Salmon, Scott I. Bearman, E. David Crawford, Brent A. Blumenstein, Shaji Kumar and Angela Dispenzieri and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.
In The Last Decade
Vivek Roy
189 papers receiving 6.0k citations
Hit Papers
Author Peers
Peers are selected by citation overlap in the author's most active subfields. citations · hero ref
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Vivek Roy | 2.9k | 2.8k | 2.4k | 1.5k | 808 | 203 | 6.1k | |
| Scott I. Bearman | 1.1k 0.4× | 2.7k 1.0× | 1.7k 0.7× | 1.5k 1.0× | 670 0.8× | 59 | 5.2k | |
| Bethan Psaila | 1.9k 0.6× | 2.1k 0.8× | 1.5k 0.6× | 786 0.5× | 677 0.8× | 61 | 5.5k | |
| Roy B. Jones | 970 0.3× | 3.4k 1.2× | 2.5k 1.0× | 765 0.5× | 1.2k 1.4× | 176 | 6.6k | |
| Ajay K. Nooka | 2.9k 1.0× | 3.5k 1.3× | 3.4k 1.4× | 365 0.2× | 623 0.8× | 282 | 6.0k | |
| Victor M. Santana | 2.0k 0.7× | 643 0.2× | 2.0k 0.8× | 1.4k 1.0× | 558 0.7× | 148 | 5.4k | |
| Paul S. Gaynon | 2.0k 0.7× | 5.1k 1.8× | 2.4k 1.0× | 493 0.3× | 1.1k 1.3× | 193 | 11.5k | |
| D Maraninchi | 1.3k 0.4× | 3.7k 1.3× | 3.8k 1.6× | 885 0.6× | 1.0k 1.3× | 259 | 8.5k | |
| W M Crist | 1.4k 0.5× | 1.9k 0.7× | 2.0k 0.9× | 1.9k 1.3× | 563 0.7× | 75 | 6.1k | |
| Patrick J. Stiff | 1.4k 0.5× | 3.2k 1.2× | 4.1k 1.7× | 1.4k 0.9× | 1.2k 1.5× | 247 | 8.4k | |
| Bernhard Wörmann | 1.9k 0.7× | 3.3k 1.2× | 1.9k 0.8× | 621 0.4× | 1.5k 1.9× | 173 | 6.3k |
Countries citing papers authored by Vivek Roy
Since
Specialization
Citations
This map shows the geographic impact of Vivek Roy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek Roy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek Roy more than expected).
Fields of papers citing papers by Vivek Roy
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Vivek Roy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek Roy. The network helps show where Vivek Roy may publish in the future.
Co-authorship network of co-authors of Vivek Roy
This figure shows the co-authorship network connecting the top 25 collaborators of Vivek Roy. A scholar is included among the top collaborators of Vivek Roy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek Roy. Vivek Roy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ailawadhi, Sikander, Ryan D. Frank, David O. Hodge, et al.. (2024). Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities. Blood Cancer Journal. 14(1). 86–86.
2.
Baranwal, Anmol, Mohamed A. Kharfan‐Dabaja, Ernesto Ayala, et al.. (2024). Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide. Transplantation and Cellular Therapy. 31(1). 16.e1–16.e9.
3.
Parrondo, Ricardo, et al.. (2023). Patient Awareness of CAR-T and Bispecific Antibody Treatments for Multiple Myeloma: Real-World Learnings and Disparities. Blood. 142(Supplement 1). 2418–2418.
4.
Visram, Alissa, Suzanne R. Hayman, Angela Dispenzieri, et al.. (2023). A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL ). American Journal of Hematology. 98(8). 1277–1285.
5.
Jiang, Liuyan, Zhuo Li, Hemant S. Murthy, et al.. (2023). Detectable Somatic Variants Using Next Generation Sequencing (NGS) Post Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Predict for High Relapse Risk in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Blood. 142(Supplement 1). 4983–4983.
6.
Ailawadhi, Sikander, Ricardo Parrondo, Vivek Roy, et al.. (2023). The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers. Cancer Medicine. 12(18). 19013–19020.
7.
Kharfan‐Dabaja, Mohamed A., Vivek Roy, Hemant S. Murthy, et al.. (2023). Post-Autologous Hematopoietic Cell Transplant Care in the “Home Sweet Home” Setting: A Treatment Paradigm Shift. Hematology/Oncology and Stem Cell Therapy. 16(4). 407–411.
8.
Ailawadhi, Sikander, Ricardo Parrondo, Muhamad Alhaj Moustafa, et al.. (2022). Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematological Oncology. 40(4). 695–703.
9.
Iqbal, Madiha, Jonas Paludo, Allison Rosenthal, et al.. (2021). Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 22(2). e89–e95.
10.
Jain, Tania, Katie L. Kunze, Luke Mountjoy, et al.. (2020). Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer Journal. 10(3). 36–36.
11.
Rahman, Zaid Abdel, Hollie Saunders, Allison Rosenthal, et al.. (2020). C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel ☆. Hematology/Oncology and Stem Cell Therapy. 14(2). 141–146.
12.
Kumar, Vivek, Sikander Ailawadhi, Aditya Mehta, et al.. (2019). Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer Journal. 9(10). 75–75.
13.
Jain, Tania, Katie L. Kunze, M’hamed Temkit, et al.. (2018). Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplantation. 54(2). 204–211.
14.
Tefferi, Ayalew, Jeanne Palmer, James L. Slack, et al.. (2018). Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. American Journal of Hematology. 93(5). 649–654.
15.
Hashmi, Shahrukh K., Maria Stevens, Angelina D. Tan, et al.. (2018). Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. Hematology/Oncology and Stem Cell Therapy. 12(3). 155–160.
16.
Dholaria, Bhagirathbhai, Prakash Vishnu, Vivek Roy, et al.. (2017). DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B- Cell Lymphoma: The Mayo Clinic Florida Experience. Blood. 130. 1572–1572.
17.
Paulus, Aneel, Marie V. Coignet, Alak Manna, et al.. (2017). Comparative Analysis of Gene Expression Status to Predict Response to Initial Multiple Myeloma Treatment: Utility of the Mmrf Commpass Database in Validating Historical Findings. Blood. 130. 2178–2178.
18.
Reinholz, Monica M., Kathleen Tenner, David W. Hillman, et al.. (2011). Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437. Clinical Cancer Research. 17(22). 7183–7193.
19.
Lacy, Martha Q., Suzanne R. Hayman, Morie A. Gertz, et al.. (2009). Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology. 27(30). 5008–5014.
20.
Roy, Vivek & Edith A. Perez. (2009). Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2–Positive Breast Cancer. The Oncologist. 14(11). 1061–1069.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Scott I. Bearman Breakdown of academic impact, for papers by Bethan Psaila Breakdown of academic impact, for papers by Roy B. Jones Breakdown of academic impact, for papers by Ajay K. Nooka Breakdown of academic impact, for papers by Victor M. Santana Breakdown of academic impact, for papers by Paul S. Gaynon Breakdown of academic impact, for papers by D Maraninchi Breakdown of academic impact, for papers by W M Crist Breakdown of academic impact, for papers by Patrick J. Stiff Breakdown of academic impact, for papers by Bernhard Wörmann